Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction-Reference-Cited by-同舟云学术

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction

Published:2017-11-15 Issue: Volume: Page:
ISSN:1424-3997
Container-title:Swiss Medical Weekly
language:en
Short-container-title:Swiss Med Wkly

Author:

Ademi Zanfina¹,Pfeil Alena M.²,Hancock Elizabeth³,Trueman David⁴,Haroun Rola Haroun⁵,Deschaseaux Celine⁵,Schwenkglenks Matthias²

Affiliation:

1. Institute of Pharmaceutical Medicine (ECPM), University of Basel, Switzerland, and Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

2. Institute of Pharmaceutical Medicine (ECPM), University of Basel, Switzerland

3. PHMR, London, United Kingdom

4. Source HEOR, Oxford, United Kingdom

5. Novartis Pharma AG, Basel, Switzerland

Publisher

EMH Swiss Medical Publishers, Ltd.

Subject

General Medicine

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framework for developing cost-effectiveness analysis threshold: the case of Egypt;Journal of the Egyptian Public Health Association;2024-06-03

2. Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan;Pharmacia;2024-02-08

3. Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review;Value in Health;2023-10

4. Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran;Health Economics Review;2023-09-04

5. Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina;Health Economics Review;2023-02-18